The 20-Year Future of San Diego Biotech, Coming March 31

3/9/10Follow @xconomy

A wise man once said that overnight success in biotech takes about 15 years. All kidding aside, we at Xconomy recognize that real innovation in life sciences doesn’t just pop out of the blue on a quarterly time horizon. So we thought it would be worthwhile to ask some of San Diego’s scientific and business leaders to share their long-range visions of what the San Diego life sciences cluster can achieve over the next two decades.

This event, coming up on the evening of March 31 at Biogen Idec’s San Diego office, will feature an interactive panel discussion with Paul Schimmel of The Scripps Research Institute, Dan Bradbury of Amylin Pharmaceuticals, and Fred “Rusty” Gage of the Salk Institute. John Mendlein, the chairman of Fate Therapeutics, will moderate. This stellar panel will be followed by quick 3-minute “burst” presentations by a handful of organizations pursuing innovative biotech ideas in San Diego—Ambrx, Biogen Idec New Ventures, Helixis, Receptos, and VentiRx Pharmaceuticals.

Ever since we first announced this event in mid-February, tickets have been going fast. I’m writing today to remind you that tomorrow is the final day you can buy discounted early-bird tickets for $75. We expect this event to sell out before March 31, so it’s best to get your tickets in advance. You can find all the pertinent details on how to register by clicking here.

I will personally fly in from Seattle to be there to facilitate audience interaction with our great lineup of speakers. I’m also looking forward to networking with a lot of our regular readers at the reception afterwards. Maybe you can enlighten me, and the rest of our growing national readership, on what you think will transform the life sciences business over the next 20 years.

By posting a comment, you agree to our terms and conditions.